Advancing the Cell Therapy Industry

About PCT

PCT is the global contract development and manufacturing services platform of the Hitachi Chemical Regenerative Medicine Business Sector, represented in the United States by Hitachi Chemical Advanced Therapeutics Solutions, LLC, a leading external development and manufacturing partner that focuses exclusively on the cell therapy industry.

We offer industry-leading cell therapy development and manufacturing expertise to:

  • Accelerate your progress to market

  • Anticipate and overcome challenges on the way to commercialization

  • Reduce the overall costs and risks of your clinical development program 

PCT’s resources and capabilities help clients overcome the unique challenges presented by cell therapy manufacturing as product candidates approach commercialization, and help better position the therapeutic for long-term viability.

To provide our clients with high value development and manufacturing services to advance commercialization of cellular therapies
A world in which transformative therapeutics are accessible to all

What should I look for in a critical
development and manufacturing partner?


Why PCT?

Proven track record of success: Only CMO to see client’s cell therapy product receive approval from the FDA for commercial sale.

Unparalleled Cell Therapy Development and Manufacturing Expertise

More than 200 employees—including more than 10 PhDs—offer deep and diverse therapeutic platform experience in the areas of immunotherapy, cell-based gene therapy, hematopoietic replacement and tissue repair/regeneration. As part of our Manufacturing Sciences and Technology group, our bioengineers study existing tools and develop new approaches to increase the reliability of cell therapy manufacturing processes reduce the cost of goods and deliver the necessary quality standards for your clinical applications.

Two U.S. cGMP Facilities and Extensive Capabilities and Continued Expansion in 2019

PCT has cGMP-compliant, state-of-the art facilities in the NY/NJ area and California to serve the cell therapy industry. We offer cGMP infrastructure for the manufacturing of cell therapy-based products including quality systems, streamlined technology transfer, storage and logistics, and cell and tissue processing.  Our Center for Innovation and Engineering offers process and analytical development, engineering solutions and consulting services. An additional facility in New Jersey is expected to launch manufacturing capability in mid-2019. Outside of the U.S, a facility in Yokohama, Japan, opened in 2018 and the acquisition of apceth Biopharma, to add European capabilities, completed in April 2019.  For more information on our capabilities, click the link below to download our capabilities brochure now.

Download Capabilities Brochure

 HCATS 2019 Overview Brochure



Technology Transfers
Technology Transfers


Products Manufactured
Products Manufactured


Patients Treated
Patients Treated


Clients Served
Clients Served

Dedicated to Client Service

Our client-focused approach is designed to deliver world-class service. We earn the trust of our clients because for us it’s about developing the long-term relationships built upon satisfaction with the PCT experience. Our goal is to be viewed as your partner, an extension of your in-house team, by delivering the expertise, strategy, teamwork, efficiency and accessibility you demand.

At PCT, your milestones are our milestones. Timely achievement of clinical milestones is essential to the success of a development-stage cell therapy company. We know this is the lifeblood of our clients. After your project plan is established, PCT will partner with you to do what is needed to keep your program on track and to ensure that you meet applicable quality standards, through regulatory approval and beyond.

We are a partner in your progress to commercial-phase manufacturing, making continuous investments in best-in-class technologies, quality systems and human resources.

Contact Us